Regulation & Industry7 Published Reports

Maya Chen

Regulatory Affairs Correspondent • Senior Regulatory Journalist

Maya covers federal regulatory rulings, FDA Pharmacy Compounding Advisory Committee votes, DOJ/FTC enforcement actions, and international supply chain standards across North American and Pacific biotech sectors.

Focus Beats:FDA RegulationsPharmacy CompoundingPolicy & LegislationBiotech Supply ChainsCategory 1/2 Reviews

Twitter / X LinkedIn Contact Desk

Articles & Investigations by Maya Chen

Showing 7 reports

approval-and-legality•2026-08-20

Are Peptides Legal? FDA Tiers, Compounding Bans, and the 2026 Regulatory Gap

By Maya Chen

industry•2026-08-20

Eli Lilly Files Six Federal Lawsuits to Dismantle the Retatrutide 'Research-Use Only' Mark

By Maya Chen

approval-and-legality•2026-08-20

FDA-Approved Peptides: What Approval Actually Means

By Maya Chen

regulation•2026-08-20

FDA Panel Backs Compounding of Four Unapproved Peptides

By Maya Chen

regulation•2026-08-20

FDA Staff Opposed All Seven Peptides. The Advisory Panel Overruled Them.

By Maya Chen

regulation•2026-08-20

Inside the FDA Vote: How the 'RFK Jr. Effect' Reshaped Peptide Policy

By Maya Chen

regulation•2026-08-20

FDA Advisory Panel Sides With Kennedy's Peptide Agenda Over Its Own Scientists' Warnings

By Maya Chen